Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 -0.76%25 Days Payable is 33.56 as of Dec. 2025, which is 413% above its 10-year median of 6.54. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, DuoGenic StemCells ranks worse than 83.48% on this metric.
The historical rank and industry rank for DuoGenic StemCells's Days Payable or its related term are showing as below:
ROCO:7607'
s Days Payable Range Over the Past 10 Years
Min: 4.43 Med: 6.54 Max: 26.5
Current: 26.5
During the past 5 years, DuoGenic StemCells's highest Days Payable was 26.50. The lowest was 4.43. And the median was 6.54.
ROCO:7607's Days Payable is ranked worse than 83.48% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs ROCO:7607: 26.50
DuoGenic StemCells's Days Payable
increased
from Dec. 2024 (4.87) to Dec. 2025 (33.56).
It may suggest that DuoGenic StemCellsdelayed paying its suppliers.
DuoGenic StemCells Days Payable Related Terms
DuoGenic StemCells Days Payable Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Days Payable distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
DuoGenic StemCells's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Days Payable of 33.56 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DuoGenic StemCells and its competitors. This is 413% above median its historical median of 6.54. Over the past decade, DuoGenic StemCells' Days Payable has ranged from 4.43 to 26.50. According to the industry distribution chart, DuoGenic StemCells ranks #586 out of 702 companies in the Biotechnology industry, placing it in the top 83.5%.
Is DuoGenic StemCells' Days Payable too high?
DuoGenic StemCells' current Days Payable of 33.56 is 413% above median its 10-year median of 6.54. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 26.50. The Biotechnology industry median Days Payable is 113.10. DuoGenic StemCells' value of 33.56 is 70.3% below this industry median. Based on the distribution chart, DuoGenic StemCells ranks #586 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #586 out of 702 companies for Days Payable. This places DuoGenic StemCells in the lower half of its industry. The industry median Days Payable is 113.10. DuoGenic StemCells' value of 33.56 is 70.3% below this benchmark. Historically, DuoGenic StemCells' own Days Payable has ranged from 4.43 to 26.50 over the past decade. While the company's 10-year median is 6.54 vs. the industry median of 113.10, DuoGenic StemCells has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Days Payable of 33.56 is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Days Payable is 33.56, which is 413% above median its own 10-year median of 6.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Days Payable is 33.56, which is 413% above median its 10-year median of 6.54 and 70.3% below the Biotechnology industry median of 113.10. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Days Payable is 33.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Days Payable: 33.56 (413% above median its 10-year median of 6.54)
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
Industry Position: 70.3% below the Biotechnology median (#586 of 702)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
